REG - Nuformix PLC - Results of Underwritten Open Offer

NuformixAnnouncement

12/11/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251112:nRSL1268Ha&default-theme=true

RNS Number : 1268H  Nuformix PLC  12 November 2025

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND FOR
INFORMATION PURPOSES ONLY AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION,
IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, AND DOES NOT CONSTITUTE AN OFFER
OF SECURITIES FOR SALE IN, INTO OR FROM THE UNITED STATES OF AMERICA,
AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER
JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION, DISTRIBUTION, OFFER OR SALE
WOULD BE UNLAWFUL.

 

THIS ANNOUNCEMENT IS FOR INFORMATION PURPOSES ONLY AND DOES NOT CONSTITUTE OR
CONTAIN ANY INVITATION, SOLICITATION, RECOMMENDATION, OFFER OR ADVICE TO ANY
PERSON TO PURCHASE AND/OR SUBSCRIBE FOR, OTHERWISE ACQUIRE OR DISPOSE OF ANY
SECURITIES IN NUFORMIX PLC OR ANY OTHER ENTITY IN ANY JURISDICTION. NEITHER
THIS ANNOUNCEMENT NOR THE FACT OF ITS DISTRIBUTION, SHALL FORM THE BASIS OF,
OR BE RELIED ON IN CONNECTION WITH ANY INVESTMENT DECISION IN RESPECT OF
NUFORMIX PLC.

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF
THE MARKET ABUSE REGULATIONS (EU) NO. 596/2014 WHICH FORMS PART OF DOMESTIC UK
LAW PURSUANT TO THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").

 

12 November 2025

 

Nuformix plc

 

("Nuformix" or the "Company")

 

Results of Underwritten Open Offer

 

Total voting rights

 

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet
medical needs in fibrosis and oncology via drug repurposing, announces the
results of its underwritten Open Offer to Qualifying Shareholders which was
announced on 28 October 2025 and closed for acceptances, in accordance with
its terms, on 11 November 2025.

 

The Company announces that valid acceptances have been received from
Qualifying Shareholders for a total of 465,813,047 Open Offer Shares,
representing a take-up of approximately 408.5% of the 114,040,535 Open Offer
Shares available.

 

All Qualifying Shareholders who have validly applied for Open Offer Shares
will receive their full Basic Entitlement. Applications for Open Offer Shares
under the Excess Application Facility will be scaled back on a pro-rata basis,
with the same scaling methodology to be applied to each Shareholder who
applied for Excess Entitlements. Accordingly, subject to Admission becoming
effective, 114,040,535 Open Offer Shares will be issued in connection with the
Open Offer, raising approximately £228,081 (before expenses) for the Company
at the Issue Price of 0.2 pence per Open Offer Share.

 

Capitalised terms used but not otherwise defined in this announcement bear the
meanings ascribed to them in the Circular posted to shareholders on 28 October
2025.

 

Director participation in the Open Offer

 

The Directors have participated in the Open Offer, as follows:

 

 Director           No. of Ordinary Shares currently held  % of Existing Ordinary Shares  Number of Open Offer Shares subscribed for  No. of Ordinary Shares held on Admission()  % of the Enlarged Share Capital
 Julian Gilbert     22,250,000*                            1.11                           1,271,428                                   23,521,428                                  1.11
 Daniel Gooding     49,500,000**                           2.48                           2,828,571                                   52,328,571                                  2.48
 Madeleine Kennedy  22,250,000***                          1.11                           1,271,428                                   23,521,428                                  1.11

* held beneficially through Hargreaves Lansdown (Nominees)

* 37,500,000 of which are held beneficially through Interactive Investor
Services and 12,000,000 of which are held through Hargreaves Lansdown
(Nominees)

*** held beneficially through a nominee appointed by the trading platform, IG
Trading and Investments Ltd

 

The notifications below, made in accordance with the requirements of the EU
Market Abuse Regulation (2014/596/EU) as it forms part of United Kingdom
domestic law by virtue of the European Union (Withdrawal) Act 2018 and as
modified by or under the European Union (Withdrawal) Act 2018 or other
domestic law, provides further detail.

 

Admission and dealings

 

The Open Offer Shares will, when issued, be credited as fully paid and will
rank pari passu in all respects with each other and with the Existing Ordinary
Shares, including the right to receive all dividends and other distributions
declared, made or paid after the date of Admission. Application has been made
to the FCA for the Open Offer Shares to be admitted to the equity shares
(transition) category of the Official List in accordance with Chapter 22 of
the UKLR and to the London Stock Exchange plc for such Open Offer Shares to be
admitted to trading on the London Stock Exchange's main market for listed
securities ("Admission"). Dealings in the Open Offer Shares and Admission are
expected to take place on or around 8.00 a.m. on 13 November 2025.

 

Total voting rights

 

In accordance with the Financial Conduct Authority's Disclosure, Guidance and
Transparency Rules, the Company confirms that following Admission, the
Company's enlarged issued ordinary share capital will comprise 2,109,749,903
Ordinary Shares. The Company does not hold any shares in Treasury.
Therefore, from Admission, the total number of voting rights in the Company
will be 2,109,749,903 and this figure may be used by shareholders in the
Company as the denominator for the calculations to determine if they are
required to notify their interest in, or a change to their interest in the
Company, under the Disclosure Guidance and Transparency Rules.

 

Enquiries:

 Nuformix plc
 Dr Dan Gooding, Executive Director  Via IFC Advisory

 CMC Markets
 Douglas Crippen                     +44 (0) 20 3003 8632

 IFC Advisory Limited
 Tim Metcalfe                        +44 (0) 20 3934 6630

 Zach Cohen                          nuformix@investor-focus.co.uk

 

Notification and public disclosure of transactions by persons discharging
managerial responsibilities and persons closely associated with them.

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Julian Gilbert
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Chairman
 b)  Initial notification/ Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Nuformix plc
 b)  LEI                                                          2138003XG3H3I2J3BJ24
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of nominal value 0.05 pence

     Identification code

                                                                  GB00BYW79Y38
 b)  Nature of the transaction                                    Subscription of new Ordinary Shares pursuant to Open Offer
 c)  Price(s) and volume(s)

                                                                  Price(s) Volume(s)

                                                                  0.20 pence

                                                                  1,271,428
 d)  Aggregated information

     - Aggregated volume                                          1,271,428

     - Price                                                      £2,542.86
 e)  Date of the transaction                                      11 November 2025
 f)  Place of the transaction                                     Outside a trading venue

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Madeleine Kennedy
 2   Reason for the notification
 a)  Position/status                                              Non-Executive Director
 b)  Initial notification/ Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Nuformix plc
 b)  LEI                                                          2138003XG3H3I2J3BJ24
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of nominal value 0.05 pence

     Identification code

                                                                  GB00BYW79Y38
 b)  Nature of the transaction                                    Subscription of new Ordinary Shares pursuant to Open Offer
 c)  Price(s) and volume(s)

                                                                  Price(s) Volume(s)

                                                                  0.20 pence

                                                                  1,271,428
 d)  Aggregated information

     - Aggregated volume                                          1,271,428

     - Price                                                      £2,542.86
 e)  Date of the transaction                                      11 November 2025
 f)  Place of the transaction                                     Outside a trading venue

 

 1   Details of the person discharging managerial responsibilities/person closely
     associated
 a)  Name                                                         Daniel Gooding
 2   Reason for the notification
 a)  Position/status                                              Executive Director
 b)  Initial notification/ Amendment                              Initial Notification
 3   Details of the issuer, emission allowance market participant, auction
     platform, auctioneer or auction monitor
 a)  Name                                                         Nuformix plc
 b)  LEI                                                          2138003XG3H3I2J3BJ24
 4   Details of the transaction(s): section to be repeated for (i) each type of
     instrument; (ii) each type of transaction; (iii) each date; and (iv) each
     place where transactions have been conducted
 a)  Description of the financial instrument, type of instrument  Ordinary shares of nominal value 0.05 pence

     Identification code

                                                                  GB00BYW79Y38
 b)  Nature of the transaction                                    Subscription of new Ordinary Shares pursuant to Open Offer
 c)  Price(s) and volume(s)

                                                                  Price(s) Volume(s)

                                                                  0.20 pence

                                                                  2,828,571
 d)  Aggregated information

     - Aggregated volume                                          2,828,571

     - Price                                                      £5,657.14
 e)  Date of the transaction                                      11 November 2025
 f)  Place of the transaction                                     Outside a trading venue

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOEBLBDBCUBDGUB



            Copyright 2019 Regulatory News Service, all rights reserved